Literature DB >> 20226762

PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity.

Xiaoyang Hou1, Ying H Shen, Chuanbao Li, Fei Wang, Cheng Zhang, Peili Bu, Yun Zhang.   

Abstract

Oxidative stress has been shown to play an important role in the development of hypertensive renal injury. Peroxisome proliferator-activated receptors alpha (PPARalpha) has antioxidant effect. In this study, we demonstrated that fenofibrate significantly reduced proteinuria, inflammatory cell recruitment and extracellular matrix (ECM) proteins deposition in the kidney of SHRs without apparent effect on blood pressure. To investigate the mechanisms involved, we found that fenofibrate treatment markedly reduced oxidative stress accompanied by reduced activity of renal NAD(P)H oxidase, increased activity of Cu/Zn SOD, and decreased phosphorylation of p38MAPK and JNK in the kidney of SHRs. Taken together, fenofibrate treatment can protect against hypertensive renal injury without affecting blood pressure by inhibiting inflammation and fibrosis via suppression of oxidative stress and MAPK activity. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20226762     DOI: 10.1016/j.bbrc.2010.03.043

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

1.  Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy.

Authors:  Sumon Roy; Dongjoon Kim; Cristina Hernández; Rafael Simó; Sayon Roy
Journal:  Exp Eye Res       Date:  2015-08-18       Impact factor: 3.467

2.  The role of nuclear receptors in the kidney in obesity and metabolic syndrome.

Authors:  Claudia Tovar-Palacio; Nimbe Torres; Andrea Diaz-Villaseñor; Armando R Tovar
Journal:  Genes Nutr       Date:  2012-04-25       Impact factor: 5.523

Review 3.  Conflicting roles of 20-HETE in hypertension and renal end organ damage.

Authors:  Chao Zhang; George W Booz; Qing Yu; Xiaochen He; Shaoxun Wang; Fan Fan
Journal:  Eur J Pharmacol       Date:  2018-06-07       Impact factor: 4.432

4.  Anticancer activity of salicin and fenofibrate.

Authors:  Marwa Sabaa; Hassan M ELFayoumi; Shimaa Elshazly; Mahmoud Youns; Waleed Barakat
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-21       Impact factor: 3.000

Review 5.  Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.

Authors:  Fan Fan; Richard J Roman
Journal:  J Am Soc Nephrol       Date:  2017-07-12       Impact factor: 10.121

6.  Differentiation and Induced Sensorial Alteration of the Coronal Organ in the Asexual Life of a Tunicate.

Authors:  Lucia Manni; Chiara Anselmi; Paolo Burighel; Margherita Martini; Fabio Gasparini
Journal:  Integr Comp Biol       Date:  2018-08-01       Impact factor: 3.326

7.  Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability.

Authors:  Kyle Trudeau; Sumon Roy; Wen Guo; Cristina Hernández; Marta Villarroel; Rafael Simó; Sayon Roy
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-11       Impact factor: 4.799

Review 8.  Lipotoxicity as a trigger factor of renal disease.

Authors:  Adriana Izquierdo-Lahuerta; Cristina Martínez-García; Gema Medina-Gómez
Journal:  J Nephrol       Date:  2016-03-08       Impact factor: 3.902

9.  Fenofibrate, a PPARα agonist, protect proximal tubular cells from albumin-bound fatty acids induced apoptosis via the activation of NF-kB.

Authors:  Nan Zuo; Xiaoyu Zheng; Hanzhe Liu; Xiaoli Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Role of PPARα and Its Agonist in Renal Diseases.

Authors:  Ching-Feng Cheng; Hsi-Hsien Chen; Heng Lin
Journal:  PPAR Res       Date:  2010-11-08       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.